InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
董事已披露买入
1
已披露卖出
1
T+90 胜率
100%
T+90 平均收益
+0.5%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the full record of transactions filed by Katabi Maha, 董事. Director active across 3 companies, notably Vera Therapeutics, Inc.. In total, 6 disclosures have been published. Split: 1 buy · 1 sell. Total volume traded: €5.9m. Activity tracked since 30 January 2024. The latest transaction was disclosed on 21 March 2024 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Katabi Maha
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
32,756 股@ US$43.0021.8% 占其流量Class A Common StockSEC:0001104659-24-038589:0
1,209,764 股@ US$62.50100.0% 占其流量Common StockSEC:0001415889-24-005511:0
161,290 股@ US$31.0078.2% 占其流量Class A Common StockSEC:0001104659-24-009537:0
标准退出：2024年4月29日 (T+90)
973,653 股Common StockSEC:0001209191-23-050305:0
3,401,544 股Common StockSEC:0001104659-21-089437:0
2,187,504 股Class A Common StockSEC:0001209191-21-033812:0
6 条申报中的 6 条
About Katabi Maha
Maha Katabi is a Director at Vera Therapeutics, Inc. and Aerovate Therapeutics, Inc. In this role, she contributes to the strategy and governance of the companies. Vera Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases, while Aerovate Therapeutics, Inc. focuses on respiratory therapies. Maha Katabi brings valuable expertise in biotechnology and healthcare.
